Heart Failure Beat: Constructive Disruption with the JCF Editors

The program's hosts, Michael Beasley, MD, and Priya Umapathi, MD, chat with the editors of the Journal of Cardiac Failure (JCF) about what constructive disruption to scientific publishing means, touching on broad inclusion, double-blind peer reviews within seven days, being a platform for critical documents that help to define the field, mentorship, and what’s on the horizon for the JCF.

Constructive Disruption with the JCF Editors

Priya and Michael chat with the editors of the Journal of Cardiac Failure (JCF) about what constructive disruption to scientific publishing means, touching on broad inclusion, double-blind peer reviews within seven days, being a platform for critical documents that help to define the field, mentorship, and what’s on the horizon for the JCF.

Listen below and subscribe: Apple PodcastsGoogle Podcasts, SpotifyPodcast Home

Hosts: 

  • Michael Beasley, MD, Assistant Professor of Medicine at the Yale School of Medicine @MHBeasleyMD

  • Priya Umapathi, MD, Assistant Professor in the Division of Cardiology & Advanced Heart Failure and Heart Transplant Cardiologist at Johns Hopkins Hospital @priyaumapathi

Guests: 

  • Anuradha Lala-Trindade (Anu Lala), MD, Deputy Editor, Journal of Cardiac Failure, Associate Professor of Medicine, Mount Sinai Hospital
     

  • Robert J. Mentz, MD, Editor-in-Chief, Journal of Cardiac Failure, Chief, Heart Failure Section, Duke University



Guest Disclosures

Dr. Robert J. Mentz received research support and honoraria from Abbott, American Regent, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Boston Scientific, Cytokinetics, Fast BioMedical, Gilead, Innolife, Eli Lilly, Medtronic, Medable, Merck, Novartis, Novo Nordisk, Pfizer, Pharmacosmos, Relypsa, Respicardia, Roche, Rocket Pharmaceuticals, Sanofi, Verily, Vifor, Windtree Therapeutics, and Zoll.